van Hoefen Wijsard Milo, Serné Saskia H, Otten René H, Bosscha Machteld I, Dommering Charlotte J, Fabius Armida W, Moll Annette C
Department of Ophthalmology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, 1081 HV Amsterdam, The Netherlands.
Medical Library, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.
Cancers (Basel). 2021 Apr 17;13(8):1942. doi: 10.3390/cancers13081942.
The aim of this systematic review is to assess the latest age at diagnosis for detection of familial retinoblastoma in order to evaluate at what age screening of at-risk children could be discontinued. Extended screening beyond this age would result in unnecessary patient burden and costs. However, discontinuing screening prematurely would have the adverse effect of missing tumors. We performed a literature search (PubMed, Embase, CINAHL and the Cochrane Library) up until February of 2021 and systematically included studies where patients had a family history of retinoblastoma, a known age at diagnosis, and who were ophthalmologically screened for retinoblastoma from birth. A total of 176 familial retinoblastoma patients from 17 studies were included in this review. Based on 48 months of age being the latest age of diagnosis, ophthalmological screening for familial retinoblastoma could safely be discontinued at age four years.
本系统评价的目的是评估家族性视网膜母细胞瘤诊断的最晚年龄，以便评估在什么年龄可以停止对高危儿童的筛查。超过这个年龄进行延长筛查会给患者带来不必要的负担和费用。然而，过早停止筛查会产生漏诊肿瘤的不良后果。我们进行了文献检索（截至2021年2月检索了PubMed、Embase、CINAHL和Cochrane图书馆），并系统纳入了有视网膜母细胞瘤家族史、已知诊断年龄且从出生起就接受视网膜母细胞瘤眼科筛查的患者的研究。本评价共纳入了17项研究中的176例家族性视网膜母细胞瘤患者。基于48个月龄是最晚诊断年龄，家族性视网膜母细胞瘤的眼科筛查可以在4岁时安全停止。
